NO962322D0 - Substituerte N-(indol-2-karbonyl)--alanimamider og derivater som antidiabetiske midler - Google Patents

Substituerte N-(indol-2-karbonyl)--alanimamider og derivater som antidiabetiske midler

Info

Publication number: NO962322D0
Authority: NO; Norway
Prior art keywords: alanimamides; indole; carbonyl; derivatives; substituted
Prior art date: 1995-06-06

Application number

NO962322A

Other languages

English (en)

Other versions

NO307335B1 (no

NO962322L (no

Inventor

Bernard Hulin

Judith Lee Treadway

William Holt Martin

Dennis Jay Hoover

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-06

Filing date

1996-06-05

Publication date

1996-06-05

1996-06-05 Application filed by Pfizer filed Critical Pfizer

1996-06-05 Publication of NO962322D0 publication Critical patent/NO962322D0/no

1996-12-09 Publication of NO962322L publication Critical patent/NO962322L/no

2000-03-20 Publication of NO307335B1 publication Critical patent/NO307335B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO962322A 1995-06-06 1996-06-05 Substituerte N-(indol-2-karbonyl)-<beta>-alaninamider, anvendelse derav og farmasøytisk preparat NO307335B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CA002223625A CA2223625C (en)	1995-06-06	1995-06-06	Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
PCT/IB1995/000443 WO1996039385A1 (en)	1995-06-06	1995-06-06	Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Publications (3)

Publication Number	Publication Date
NO962322D0 true NO962322D0 (no)	1996-06-05
NO962322L NO962322L (no)	1996-12-09
NO307335B1 NO307335B1 (no)	2000-03-20

Family

ID=25679897

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO962322A NO307335B1 (no)	1995-06-06	1996-06-05	Substituerte N-(indol-2-karbonyl)-<beta>-alaninamider, anvendelse derav og farmasøytisk preparat

Country Status (40)

Country	Link
US (1)	US6297269B1 (no)
EP (1)	EP0832066B1 (no)
JP (1)	JP3068200B2 (no)
CN (1)	CN1374082A (no)
AP (2)	AP624A (no)
AT (1)	ATE205477T1 (no)
AU (1)	AU700887B2 (no)
BG (1)	BG62566B1 (no)
BR (1)	BR9602626A (no)
CA (1)	CA2223625C (no)
CO (1)	CO4700453A1 (no)
CZ (1)	CZ289233B6 (no)
DE (1)	DE69522718T2 (no)
DK (1)	DK0832066T3 (no)
DZ (1)	DZ2036A1 (no)
ES (1)	ES2161291T3 (no)
FI (1)	FI974437L (no)
GR (1)	GR3037075T3 (no)
HR (1)	HRP960266B1 (no)
HU (1)	HUP9601285A3 (no)
IL (1)	IL118236A0 (no)
IS (1)	IS1846B (no)
LV (1)	LV11614B (no)
MA (1)	MA23874A1 (no)
MX (1)	MX9709874A (no)
NO (1)	NO307335B1 (no)
NZ (1)	NZ286736A (no)
OA (1)	OA10459A (no)
PL (1)	PL314603A1 (no)
PT (1)	PT832066E (no)
RU (1)	RU2159613C2 (no)
SG (1)	SG45481A1 (no)
SI (1)	SI9600163A (no)
SK (1)	SK72096A3 (no)
TN (1)	TNSN96075A1 (no)
TR (1)	TR199600478A1 (no)
TW (1)	TW450961B (no)
WO (1)	WO1996039385A1 (no)
YU (1)	YU34796A (no)
ZA (1)	ZA964646B (no)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX9709874A (es) *	1995-06-06	1998-03-31	Pfizer	N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
US5952322A (en) *	1996-12-05	1999-09-14	Pfizer Inc.	Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
UA72439C2 (en)	1997-04-15	2005-03-15		Pharmaceutical compositions containing appetite suppressant agent
NZ501260A (en) *	1997-06-18	2002-09-27	Smithkline Beecham P	Treatment of diabetes with thiazolidinedione and metformin
US20020004515A1 (en) *	1997-06-18	2002-01-10	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and metformin
EP1745774A3 (en)	1997-08-11	2007-04-11	Pfizer Products Inc.	Solid pharmaceutical dispersions with enhanced bioavailability
US6150378A (en) *	1997-10-07	2000-11-21	Cephalon, Inc.	Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
US6096778A (en)	1997-10-07	2000-08-01	Cephalon, Inc.	α-ketoamide multicatalytic protease inhibitors
US6083944A (en) *	1997-10-07	2000-07-04	Cephalon, Inc.	Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
UA57811C2 (uk) *	1997-11-21	2003-07-15	Пфайзер Продактс Інк.	Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
EP1052994A2 (en)	1998-02-02	2000-11-22	Trustees Of Tufts College	Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
US5998463A (en) *	1998-02-27	1999-12-07	Pfizer Inc	Glycogen phosphorylase inhibitors
TR200003198T2 (tr) *	1998-05-01	2001-03-21	Eli Lilly And Company	sPLA2 önleyicisi ester
EP0978279A1 (en) *	1998-08-07	2000-02-09	Pfizer Products Inc.	Inhibitors of human glycogen phosphorylase
US6686335B1 (en)	1998-09-22	2004-02-03	Cephalon, Inc.	Hydroxamate-containing cysteine and serine protease inhibitors
MXPA01007099A (es)	1999-01-13	2002-03-27	Univ New York State Res Found	Metodo novedoso para disenar inhibidores de la proteina cinasa.
US6239163B1 (en)	1999-03-15	2001-05-29	Novo Nordisk A/S	Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6316489B1 (en)	1999-03-15	2001-11-13	Novo Nordisk A/S	Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6410750B1 (en) *	1999-06-18	2002-06-25	Pfizer Inc.	Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
ES2211454T3 (es) *	1999-09-30	2004-07-16	Pfizer Products Inc.	Pirrolilamidas como inhibidores de la colageno fosforilasa.
GB2355657B (en)	1999-10-27	2004-07-28	Phytopharm Plc	Inhibitors Of Gastric Acid Secretion
AU778810B2 (en)	1999-11-04	2004-12-23	Ortho-Mcneil Pharmaceutical, Inc.	Nonpeptide substituted benzothiazepines as vasopressin antagonists
PT1741445E (pt)	2000-01-21	2013-11-11	Novartis Ag	Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
CO5271699A1 (es) *	2000-01-24	2003-04-30	Pfizer Prod Inc	Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US20030040490A1 (en) *	2000-02-24	2003-02-27	Yasuo Sugiyama	Drugs containing combined active ingredients
US6555569B2 (en) *	2000-03-07	2003-04-29	Pfizer Inc.	Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AR027656A1 (es) *	2000-03-16	2003-04-09	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US6562807B2 (en) *	2000-06-23	2003-05-13	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
GB2363985B (en)	2000-06-30	2004-09-29	Phytopharm Plc	Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144507A0 (en) *	2000-07-31	2002-05-23	Pfizer Prod Inc	Use of glycogen phosphorylase inhibitors to inhibit tumor growth
US6746856B2 (en)	2000-08-09	2004-06-08	Pfizer Inc.	Microbial conversion of bicyclic heteroaromatic compounds
WO2002036066A2 (en) *	2000-11-01	2002-05-10	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia
US6821960B2 (en) *	2000-11-17	2004-11-23	Noyo Nordisk Pharmaceuticals, Inc.	Glucagon antagonists/inverse agonists
US20030037045A1 (en) *	2001-05-21	2003-02-20	Ian Melhado	Distributed computing environment for recognition of proteomics spectra
AR036711A1 (es) *	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7005445B2 (en)	2001-10-22	2006-02-28	The Research Foundation Of State University Of New York	Protein kinase and phosphatase inhibitors and methods for designing them
JP4623962B2 (ja) *	2001-10-22	2011-02-02	ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク	タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
JPWO2003037864A1 (ja) *	2001-10-29	2005-02-17	日本たばこ産業株式会社	インドール化合物及びその医薬用途
JP4771661B2 (ja)	2001-11-26	2011-09-14	トラスティーズオブタフツカレッジ	Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
WO2003045228A2 (en)	2001-11-26	2003-06-05	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
WO2003059910A1 (en) *	2002-01-18	2003-07-24	Pfizer Products Inc.	Intermediates for preparing glycogen phosphorylase inhibitors
RU2278659C9 (ru)	2002-02-01	2007-02-20	Пфайзер Продактс Инк.	Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
MXPA03000966A (es) *	2002-02-28	2003-09-04	Pfizer Prod Inc	Agentes antidiabeticos.
GB0205166D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205176D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205175D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205165D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205162D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205170D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
DE10215908B4 (de) *	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) *	2002-04-11	2005-12-18	Aventis Pharma Gmbh	Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
US6683106B2 (en)	2002-04-15	2004-01-27	Pfizer Inc.	N-(indole-2-carbonyl)-b-alaninamide crystal forms
WO2003091213A1 (en) *	2002-04-25	2003-11-06	Yamanouchi Pharmaceutical Co., Ltd.	Novel amide derivatives or salts thereof
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
DE10225635C1 (de) *	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
ATE443041T1 (de) *	2002-07-11	2009-10-15	Sanofi Aventis Deutschland	Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
CA2495943C (en) *	2002-08-29	2009-07-21	Merck & Co., Inc.	Indoles having anti-diabetic activity
UY27967A1 (es)	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
MXPA05004968A (es)	2002-11-07	2005-08-02	Pfizer Prod Inc	N-(indol-z-carbonil)amidas como agentes anti-diabeticos.
US7098235B2 (en)	2002-11-14	2006-08-29	Bristol-Myers Squibb Co.	Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
FR2847471B1 (fr) *	2002-11-25	2006-12-29	Expanscience Lab	Composition comprenant au moins un derive d'acide carbamique ,son utilisation cosmetique et comme medicament
EP1594439A2 (en)	2003-02-13	2005-11-16	Albert Einstein College Of Medicine Of Yeshiva University	REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
US20040180845A1 (en) *	2003-03-13	2004-09-16	Newgard Christopher B.	Methods and compositions for modulating glycogen synthesis and breakdown
BRPI0409465A (pt) *	2003-04-17	2006-05-02	Pfizer Prod Inc	derivados de carboxamida como agentes antidiabéticos
WO2004096768A1 (en) *	2003-04-30	2004-11-11	Pfizer Products Inc.	Anti-diabetic agents
US7405210B2 (en) *	2003-05-21	2008-07-29	Osi Pharmaceuticals, Inc.	Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
UA84146C2 (ru) *	2003-05-21	2008-09-25	Прозидион Лимитед	Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
TWI324600B (en) *	2003-07-07	2010-05-11	Kowa Co	2,4-bis (trifluoroethoxy) pyridine compound and drug containing the compound
US7576121B2 (en)	2003-11-12	2009-08-18	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1997533B8 (en)	2003-11-12	2014-10-29	Sino-Med International Alliance, Inc.	Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors
US7767828B2 (en)	2003-11-12	2010-08-03	Phenomix Corporation	Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en)	2003-11-12	2008-01-08	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP2270004A1 (en) *	2004-02-27	2011-01-05	Vertex Pharmceuticals Incorporated	Caspase inhibitors and uses thereof
EP1725555B1 (en)	2004-03-08	2010-10-06	Prosidion Ltd.	Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
JP2007527903A (ja) *	2004-03-08	2007-10-04	プロシディオン・リミテッド	インドール−２−カルボン酸ヒドラジド化合物
EP1778220A1 (en)	2004-07-12	2007-05-02	Phenomix Corporation	Constrained cyano compounds
US7365061B2 (en)	2004-11-15	2008-04-29	Bristol-Myers Squibb Company	2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) *	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en)	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en)	2004-11-15	2006-05-18	Bristol-Myers Squibb Company	2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP1819681B1 (en)	2004-11-23	2009-08-12	Warner-Lambert Company LLC	7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
WO2006059163A1 (en) *	2004-12-02	2006-06-08	Prosidion Limited	Treatment of diabetes with glycogen phosphorylase inhibitors
US7825139B2 (en)	2005-05-25	2010-11-02	Forest Laboratories Holdings Limited (BM)	Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
HRP20140091T4 (hr)	2005-09-14	2021-12-24	Takeda Pharmaceutical Company Limited	Davanje inhibitora dipeptidil peptidaze
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
BRPI0707302B8 (pt) *	2006-01-27	2021-05-25	Fibrogen Inc	compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
US7838542B2 (en)	2006-06-29	2010-11-23	Kinex Pharmaceuticals, Llc	Bicyclic compositions and methods for modulating a kinase cascade
DE102006042147A1 (de) *	2006-09-06	2008-03-27	Dynamit Nobel Gmbh Explosivstoff- Und Systemtechnik	Hydrochloride von 3-Amino-2-hydroxycarbonsäureamiden
CN101511364B (zh)	2006-09-07	2012-08-15	奈科明有限责任公司	用于糖尿病的治疗组合
BRPI0716991A2 (pt) *	2006-09-13	2013-10-08	Sanofi Aventis	DERIVADOS DE ISOSSERINA PARA USO COMO INIBIDORES DO FATOR IXa DE COAGULAÇÃO
CN101663262B (zh)	2006-12-01	2014-03-26	百时美施贵宝公司	用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2008110551A1 (en)	2007-03-12	2008-09-18	Zadec Aps	An anti-diabetic extract of rooibos
KR101207830B1 (ko)	2008-06-19	2012-12-04	다케다 야쿠힌 고교 가부시키가이샤	헤테로시클릭 화합물 및 그의 용도
AU2010232670B2 (en)	2009-04-03	2015-07-09	F. Hoffmann-La Roche Ag	Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
WO2011041293A1 (en)	2009-09-30	2011-04-07	Takeda Pharmaceutical Company Limited	Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh)	2010-02-03	2015-07-22	武田药品工业株式会社	细胞凋亡信号调节激酶1抑制剂
CA2799708A1 (en)	2010-05-21	2011-11-24	Pfizer Inc.	2-phenyl benzoylamides
US20130345392A1 (en)	2011-03-04	2013-12-26	Pfizer Inc	Edn3-like peptides and uses thereof
ES2642883T3 (es)	2011-05-31	2017-11-20	Theravance Biopharma R&D Ip, Llc	Inhibidores de neprilisina
ES2653215T3 (es)	2011-05-31	2018-02-06	Theravance Biopharma R&D Ip, Llc	Inhibidores de neprilisina
WO2012166390A1 (en) *	2011-05-31	2012-12-06	Theravance, Inc.	Neprilysin inhibitors
US20150050371A1 (en)	2012-03-09	2015-02-19	Biotropics Malaysia Berhad	Extract Formulations of Rhodamnia Cinerea And Uses Thereof
JP2016516804A (ja)	2013-04-17	2016-06-09	ファイザー・インク	心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
CN103497181B (zh)	2013-09-30	2016-03-30	承德医学院	作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途
AU2014347668A1 (en)	2013-11-05	2016-05-19	Ben-Gurion University Of The Negev Research And Development Authority	Compounds for the treatment of diabetes and disease complications arising from same
EP3110424A1 (en) *	2014-02-28	2017-01-04	Tensha Therapeutics, Inc.	Treatment of conditions associated with hyperinsulinaemia
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
AU2020209215B2 (en)	2019-01-18	2023-02-02	Astrazeneca Ab	PCSK9 inhibitors and methods of use thereof
CN115583908B (zh) *	2021-07-05	2024-08-06	西北农林科技大学	一种吲哚甲酰胺类化合物及其制备方法和用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4836846A (en)	1981-07-16	1989-06-06	E. I. Du Pont De Nemours And Company	Herbicidal indole sulfonamides
US4764610A (en)	1981-07-16	1988-08-16	E. I. Du Pont De Nemours And Company	Herbicidal indole sulfonamides
NZ202232A (en)	1981-11-06	1985-08-16	Smithkline Beckman Corp	N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
SU1227198A1 (ru) *	1982-09-29	1986-04-30	Ленинградское Ордена Ленина И Ордена Трудового Красного Знамени Производственное Объединение Мясной Промышленности	Способ получени полипептидов
US4933325A (en)	1985-08-14	1990-06-12	G. D. Searle & Co.	Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides
US4902708A (en)	1985-12-31	1990-02-20	Biomeasure, Inc.	CCK antagonists
US5089638A (en)	1986-06-16	1992-02-18	Merck & Co., Inc.	Amino acid analogs as CCK-antagonists
WO1988003022A1 (en)	1986-10-31	1988-05-05	Pfizer Inc.	Relatively low molecular weight polypeptides as renin inhibitors
US5034376A (en)	1986-10-31	1991-07-23	Pfizer Inc.	Nor-statine and nor-cyclostatine polypeptides
EP0288965A2 (de)	1987-04-29	1988-11-02	Hoechst Aktiengesellschaft	Peptide mit Phospholipase A2- hemmender Wirkung
US5128346A (en)	1987-09-21	1992-07-07	Abbott Laboratories	Derivatives of D-glutamic acid and D-aspartic acid
US5250517A (en)	1987-10-06	1993-10-05	Hoffmann-La Roche Inc.	Renin inhibiting compounds
US5346907A (en)	1988-04-05	1994-09-13	Abbott Laboratories	Amino acid analog CCK antagonists
EP0336356A3 (en)	1988-04-05	1991-09-25	Abbott Laboratories	Derivatives of tryptophan as cck antagonists
US4904846A (en)	1988-04-29	1990-02-27	Augustin Oscadal	Oil filled body heater
US5010089A (en)	1988-08-12	1991-04-23	Biomeasure, Inc.	CCK antagonists and their use in treating gastrointestinal disorders
FR2643371B1 (fr)	1989-02-17	1993-11-05	Roussel Uclaf	Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments
US4997950A (en)	1989-04-20	1991-03-05	Richard Finbar Murphy	Novel C-terminal gastrin antagonists
IE902238A1 (en)	1989-06-30	1991-01-16	Abbott Lab	Tetrapeptide type-b cck receptor ligands
IE902295A1 (en)	1989-07-07	1991-01-16	Abbott Lab	Amino acid analog cck antagonists
IE66574B1 (en)	1989-12-04	1996-01-24	Searle & Co	Heterocyclic acyl aminodiol beta-amino acid derivatives
DK0514442T3 (da)	1990-02-09	1994-09-26	Rhone Poulenc Rorer Sa	N-Phenyl-N-acetamidoglycinamider, deres fremstilling og lægemidler med indehold deraf
AU650261B2 (en)	1990-03-07	1994-06-16	Rhone-Poulenc Rorer S.A.	Derivatives of glycinamide, their preparation and medicaments containing them
FR2674522B1 (fr)	1991-03-26	1993-07-16	Lipha	Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
FR2678938B1 (fr)	1991-07-10	1993-10-08	Rhone Poulenc Rorer Sa	Derives de pyrrolidine, leur preparation et les medicaments les contenant.
GB9206757D0 (en)	1992-03-27	1992-05-13	Ferring Bv	Novel peptide receptor ligands
WO1994006755A1 (fr)	1992-09-18	1994-03-31	Japan Tobacco Inc.	Derive d'alcool presentant une activite inhibant la renine et son utilisation
WO1994007815A2 (en)	1992-09-25	1994-04-14	Abbott Laboratories	Small peptide anaphylatoxin receptor ligands
MX9709874A (es) *	1995-06-06	1998-03-31	Pfizer	N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.

1995
- 1995-06-06 MX MX9709874A patent/MX9709874A/es not_active IP Right Cessation
- 1995-06-06 ES ES95918718T patent/ES2161291T3/es not_active Expired - Lifetime
- 1995-06-06 AP APAP/P/1996/000816A patent/AP624A/en active
- 1995-06-06 WO PCT/IB1995/000443 patent/WO1996039385A1/en not_active Ceased
- 1995-06-06 FI FI974437A patent/FI974437L/fi not_active Application Discontinuation
- 1995-06-06 JP JP09500245A patent/JP3068200B2/ja not_active Expired - Fee Related
- 1995-06-06 AP APAP/P/1996/000817A patent/AP9600817A0/en unknown
- 1995-06-06 EP EP95918718A patent/EP0832066B1/en not_active Expired - Lifetime
- 1995-06-06 US US08/952,668 patent/US6297269B1/en not_active Expired - Fee Related
- 1995-06-06 AT AT95918718T patent/ATE205477T1/de not_active IP Right Cessation
- 1995-06-06 PT PT95918718T patent/PT832066E/pt unknown
- 1995-06-06 CA CA002223625A patent/CA2223625C/en not_active Expired - Fee Related
- 1995-06-06 SK SK720-96A patent/SK72096A3/sk unknown
- 1995-06-06 DE DE69522718T patent/DE69522718T2/de not_active Expired - Fee Related
- 1995-06-06 DK DK95918718T patent/DK0832066T3/da active
1996
- 1996-05-13 IL IL11823696A patent/IL118236A0/xx unknown
- 1996-05-13 IS IS4345A patent/IS1846B/is unknown
- 1996-05-14 HU HU9601285A patent/HUP9601285A3/hu unknown
- 1996-05-15 MA MA24241A patent/MA23874A1/fr unknown
- 1996-05-17 SI SI9600163A patent/SI9600163A/sl not_active IP Right Cessation
- 1996-05-17 TN TNTNSN96075A patent/TNSN96075A1/fr unknown
- 1996-05-22 DZ DZ960079A patent/DZ2036A1/fr active
- 1996-06-04 PL PL96314603A patent/PL314603A1/xx unknown
- 1996-06-04 BR BR9602626A patent/BR9602626A/pt not_active IP Right Cessation
- 1996-06-04 LV LVP-96-173A patent/LV11614B/en unknown
- 1996-06-04 BG BG100635A patent/BG62566B1/bg unknown
- 1996-06-05 CZ CZ19961627A patent/CZ289233B6/cs not_active IP Right Cessation
- 1996-06-05 ZA ZA9604646A patent/ZA964646B/xx unknown
- 1996-06-05 SG SG1996009975A patent/SG45481A1/en unknown
- 1996-06-05 NZ NZ286736A patent/NZ286736A/en unknown
- 1996-06-05 NO NO962322A patent/NO307335B1/no not_active IP Right Cessation
- 1996-06-05 RU RU96111013/14A patent/RU2159613C2/ru not_active IP Right Cessation
- 1996-06-05 AU AU54753/96A patent/AU700887B2/en not_active Ceased
- 1996-06-05 YU YU34796A patent/YU34796A/sh unknown
- 1996-06-06 OA OA60836A patent/OA10459A/en unknown
- 1996-06-06 HR HR960266A patent/HRP960266B1/xx not_active IP Right Cessation
- 1996-06-06 TR TR96/00478A patent/TR199600478A1/xx unknown
- 1996-06-06 CO CO96029520A patent/CO4700453A1/es unknown
- 1996-06-19 TW TW085107435A patent/TW450961B/zh not_active IP Right Cessation
2001
- 2001-10-30 GR GR20010401947T patent/GR3037075T3/el not_active IP Right Cessation
2002
- 2002-03-05 CN CN02106667A patent/CN1374082A/zh active Pending

Also Published As

Publication number	Publication date
CZ289233B6 (cs)	2001-12-12
CA2223625C (en)	2003-06-03
MX9709874A (es)	1998-03-31
ATE205477T1 (de)	2001-09-15
AP9600816A0 (en)	1996-07-31
JPH11500445A (ja)	1999-01-12
BG100635A (bg)	1997-09-30
IS1846B (is)	2003-02-07
HRP960266B1 (en)	2002-08-31
MA23874A1 (fr)	1996-12-31
FI974437A7 (fi)	1997-12-05
DE69522718T2 (de)	2002-02-07
PT832066E (pt)	2001-12-28
LV11614B (en)	1997-04-20
SI9600163A (en)	1997-02-28
DZ2036A1 (fr)	2002-10-22
NZ286736A (en)	2001-07-27
FI974437A0 (fi)	1997-12-05
TW450961B (en)	2001-08-21
ES2161291T3 (es)	2001-12-01
CZ162796A3 (en)	1996-12-11
LV11614A (lv)	1996-12-20
RU2159613C2 (ru)	2000-11-27
NO307335B1 (no)	2000-03-20
OA10459A (en)	2002-03-27
BR9602626A (pt)	1998-09-01
SG45481A1 (en)	1998-01-16
HUP9601285A3 (en)	2001-04-28
DE69522718D1 (en)	2001-10-18
EP0832066A1 (en)	1998-04-01
PL314603A1 (en)	1996-12-09
HRP960266A2 (en)	1997-08-31
CA2223625A1 (en)	1996-12-12
FI974437L (fi)	1997-12-05
WO1996039385A1 (en)	1996-12-12
DK0832066T3 (da)	2001-11-19
TNSN96075A1 (fr)	2005-03-15
CO4700453A1 (es)	1998-12-29
JP3068200B2 (ja)	2000-07-24
AU700887B2 (en)	1999-01-14
US6297269B1 (en)	2001-10-02
AP624A (en)	1997-12-19
HUP9601285A2 (hu)	1998-09-28
SK72096A3 (en)	1997-11-05
IL118236A0 (en)	1996-09-12
IS4345A (is)	1996-12-07
EP0832066B1 (en)	2001-09-12
HU9601285D0 (en)	1996-07-29
ZA964646B (en)	1997-12-05
GR3037075T3 (en)	2002-01-31
CN1374082A (zh)	2002-10-16
BG62566B1 (bg)	2000-02-29
TR199600478A1 (tr)	1997-03-21
AU5475396A (en)	1996-12-19
AP9600817A0 (en)	1996-07-31
NO962322L (no)	1996-12-09
YU34796A (sh)	1999-07-28

Publication	Publication Date	Title
NO990405D0 (no)	1999-01-28	Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
NO962322L (no)	1996-12-09	Substituerte N-(indol-2-karbonyl)--alanimamider og derivater som antidiabetiske midler
DK0832061T3 (da)	2001-11-19	Benzamidderivater og anvendelse deraf som vasopressin-antagonister
FI971970A7 (fi)	1997-05-07	Aniliinijohdoksia
FI944969A7 (fi)	1995-04-23	Indolijohdannaisia
FI950309A7 (fi)	1995-07-28	Proliiniamidijohdannaisia
ATE193704T1 (de)	2000-06-15	N-(3-benzofuranyl)harnstoffderivate
NO961475D0 (no)	1996-04-12	Indol-derivater
DK0755386T3 (da)	2002-08-26	Benzamid-derivater, sammensætninger indeholdende nævnte derivat og anvendelse deraf
NO972256D0 (no)	1997-05-16	O-Benzyloksimeterderivater og deres anvendelse som pesticider
NO962015D0 (no)	1996-05-15	Pyron-derivater som protease-inhibitorer og antivirus-midler
BR9606610A (pt)	1997-10-14	Herbicidas n-(1-etil-4-pirazolil) triazolazinasulfonamida
NO950327D0 (no)	1995-01-27	Pyridoindolobenzodiazepiner og derivater som antipsykotiske midler
NO963939D0 (no)	1996-09-19	N-aryl og N-alkylsulfonylaminaler som pesticider
ZA964409B (en)	1997-12-01	Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents.
DK0840609T3 (da)	2002-09-30	Anvendelse af usubstituerede og substituerede N-(pyrrol-1-yl)pyridinaminer som antikonvulsive midler
ID21408A (id)	1999-06-10	Turunan-turunan n- (4-karbamimido-fenil) -fenilglisinamid

Legal Events

Date	Code	Title	Description
2005-04-25	MM1K	Lapsed by not paying the annual fees